Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

This early-phase (Phase 1) study is testing the safety and tolerability of an oral drug called ONC206 in patients with brain tumors (primary central nervous system tumors) that have come back after previous treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of a recurrent primary brain tumor — including glioblastoma, anaplastic glioma, diffuse midline glioma, or other related tumors - You have received prior standard treatment (usually radiation and/or chemotherapy) - Your general health and organ function are adequate to tolerate the study drug **You may NOT be eligible if...** - This is your first diagnosis (not a recurrence) - You have significant uncontrolled medical conditions - You are on medications that strongly interact with the study drug - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.